Courtney Zeni, PhD

Assessing the Benefit-Risk Ratio of Approved Treatments for Bipolar Depression Using Likelihood to be Helped or Harmed (LHH) Analyses

Background: Four medications are FDA approved for acute bipolar depression: lurasidone (LUR), cariprazine (CAR), quetiapine IR & XR (QUE), and olanzapine-fluoxetine combination (OFC)....

Leslie Citrome , MD;

Robert Goldman , PhD;

Andrei Pikalov , MD, PhD;

Courtney Zeni , PhD;

10/08/2020

Efficacy and Safety of an Asenapine Transdermal System (HP-3070) for Treatment of Adults with Schizophrenia: A Phase 3 Randomized, Placebo-Controlled, Inpatient Study

Background: HP-3070, an asenapine transdermal patch for schizophrenia, offers favorable pharmacokinetics with minimal peak and trough fluctuations.

David Walling , PhD, CNS, MD;

Courtney Zeni , PhD;

Marina Komaroff , DrPH;

Leslie Citrome , MD;

Alexandra Park , BSc;

11/22/2019

Review of the trace amine-associated receptor 1 (TAAR1) agonist ulotaront: Part II - summary of initial clinical efficacy/safety results

Abstract: Introduction: Here we summarize ongoing clinical research characterizing the efficacy and safety of ulotaront as a member of the novel trace amine-associated receptor 1 (TAAR1) ...

Courtney Zeni , PhD;

01/25/2023

Review of the TAAR1 Agonist Ulotaront: Part I - From Discovery to Clinic

Abstract: Introduction: Here we provide a brief review of the discovery of ulotaront and preclinical research suggesting efficacy in schizophrenia, leading to the first clinical trial of ...

Courtney Zeni , PhD;

01/25/2023

Effect of Lurasidone on Manic Symptoms and Treatment-Emergent Mania in Children and Adolescents with Bipolar Depression

Background: The aim of these analyses was to assess the effect of lurasidone on manic symptoms and treatment-emergent (TE) mania in pediatric patients with bipolar depression.

Michael Tocco , PhD;

Robert Goldman , PhD;

Andrei Pikalov , MD, PhD;

Courtney Zeni , PhD;

10/08/2020